GeneDx Holdings Corp.

NASDAQ:WGS

Medical - Healthcare Information Services

Healthcare
$51.96 +2.69%

+$1.52 today

Market cap
$1.56B
Beta
1.97
P/E (TTM)
-21.8
EPS (TTM)
-$2.65
52W Low $32.21High $170.87

Volume 1.71M

Average 1.28M

WGS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

GeneDx Holdings Corp.NASDAQ: WGS

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows, but more slowly than its trailing trend

Q2 FY2026 revenue of $114.44M rose 11.4% year over year, behind the +25.4% change in trailing-twelve-month revenue. Sequentially, it rose 11.9% from the prior quarter. Over 3 fiscal years it compounded at +22.1% a year.

Context

  • Revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $476.01M (+11.3%) for the fiscal year ending Dec 2026, a slowdown from the +40.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$114.44M+11.9% QoQ
Last fiscal yearDec 2025
$427.54M+40.0% YoY
LTMJun 2026
$454.43M+25.4% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.4%+5.3%-6.1 pp
1 year+40.0%+11.3%-28.6 pp
3-year CAGR+22.1%+18.3%-3.8 pp
5-year CAGR+17.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
427.54M USD
Year-over-year change
+40.0%
4-year CAGR
+19.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How WGS compares with its peers on the latest reported figures

  • WGS's LTM Jun 2026 revenue of $454.43M is the 3rd highest of the 9 companies compared; the peer median is $330.13M.
  • Its year-over-year change of +25.4% is the 2nd highest of 9, against a peer median of +4.6%.
  • Over three fiscal years its annual growth of +22.1% compares with a peer median of +24.3%.
WGS Competitors Peer median
Revenue for WGS and competitors
Company Period LTM YoY 3-year CAGR
MYGNMyriad Genetics, Inc.LTM Mar 2026$829M -0.3%+6.7%
NEONeoGenomics, Inc.LTM Jun 2026$766.3M +11.2%+12.6%
WGSGeneDx Holdings Corp.LTM Jun 2026$454.43M +25.4%+22.1%
BLLNBillionToOne, Inc.LTM Jun 2026$397.41M +90.1%—
CSTLCastle Biosciences, Inc.LTM Mar 2026$339.92M -2.1%+35.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$320.35M +9.5%-19.5%
MDXHMDxHealth S.A.FY2025$107.88M +19.8%+42.8%
PSNLPersonalis, Inc.LTM Mar 2026$64.52M -24.7%—
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$1.95M -49.3%+61.8%
Peer median (excluding WGS) $330.13M+4.6%+24.3%

Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue212.2M234.69M202.57M305.45M427.54M
Cost of Revenue228.8M261.44M112.56M111.05M129.37M
Gross Profit(16.6M)(26.75M)90.01M194.4M298.17M
Gross Margin-7.8%-11.4%44.4%63.6%69.7%
Research & Development105.16M86.2M58.27M45.72M72.03M
Selling, General & Admin318.73M338.24M194.71M168.48M239.22M
Operating Expenses429.55M640.9M270.6M217.61M311.25M
Depreciation & Amortization21.81M59.31M33.73M21.95M25.22M
EBITDA(220.75M)(398.2M)(136.46M)(27.64M)6.63M
EBITDA Margin-104.0%-169.7%-67.4%-9.1%1.5%
Operating Income(446.15M)(667.65M)(180.6M)(23.21M)(11.8M)
Operating Margin-210.3%-284.5%-89.2%-7.6%-2.8%
Interest Income79K2.54M1.11M00
Interest Expense2.84M3.21M03.03M2.54M
Other Income / Expenses200.76M69.62M3.9M(29.42M)(9.34M)
Income Before Tax(245.39M)(598.03M)(176.69M)(52.63M)(21.14M)
Pre-Tax Margin-115.6%-254.8%-87.2%-17.2%-4.9%
Income Tax Expense0(49.05M)(926K)(343K)(116K)
Net Income(245.39M)(548.98M)(175.77M)(52.29M)(21.02M)
Net Margin-115.6%-233.9%-86.8%-17.1%-4.9%
EPS (Basic)(74.93)(53.63)(7.23)(1.94)(0.73)
EPS (Diluted)(74.93)(53.63)(7.23)(1.94)(0.73)
Weighted Avg Shares3.28M10.24M24.31M26.89M26.89M
Weighted Avg Shares (Diluted)3.28M10.24M24.31M26.89M26.89M

GeneDx Holdings Corp.

NASDAQ:WGS

Intrinsic Alpha fair value

Locked

Current Price

$51.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.